EP 161: How large language models can help build immunotherapies with Michelle Teng скачать в хорошем качестве

EP 161: How large language models can help build immunotherapies with Michelle Teng

In this week’s episode, Patrick is joined by Michelle Teng, ​​CEO and Co-Founder of Etcembly Ltd and Founding Executive Director and Chief Scientific Officer of SynaptixBio. Michelle explains how her team is training large language models (LLMs) to analyze immune system data and how the company’s Long Term Survivor Study is helping identify T-cell profiles associated with sustained cancer remission. She also speaks to her own experience of ultra-rare genetic disease. Show Notes: 0:00 Intro to The Genetics Podcast 01:00 Welcome to Michelle 01:35 Explaining immunotherapy and its evolution over the past decade 04:10 Current insights on immunotherapy responders and the underlying factors driving varied individual responses 05:50 The latest generation of T-cell receptor therapies 08:53 The origin of the Long Term Survivor Study, its purpose and how it informs discovery of new T-cell receptor therapies 12:32 How Etcembly is characterising T-cells and antibodies in survivor profiles 15:00 Using machine learning to understand the immune system 18:44 The complexity of Human Leukocyte Antigen (HLA) and how it relates to differences in T-cell receptor biology 22:35 T-cell repertoires in Long Term Survivor Study participants 26:06 Training LLMs in immune system biology, data and more 27:54 Michelle’s work at Immunocore and how she’s applied her knowledge to grow Etcembly 33:02 Setting up a new company at the crossroads of the Covid-19 pandemic and the inception of LLMs and AlphaFold 35:54 Current bottlenecks in pre-clinical immunotherapy development 37:23 Michelle’s eldest daughter’s experience with an ultra-rare genetic disease and the founding of SynaptixBio 43:34 Utilising biobanks and registries to better understand ultra-rare disease presentation 47:05 The power and importance of patient parent groups for developing rare disease treatments 48:48 Closing remarks Find out more www.etcembly.io www.synaptixbio.com